The specter of generic competition has long loomed above copyright’s iconic drug, Viagra, sparking questions about the prospects of similar pharmaceutical ventures. While early years saw significant profits, the intellectual property expiration has created the way for cheaper substitutes, potentially reducing revenue and presenting a genuine haza